
Biomunex to Showcase Preclinical Findings on Its MAIT Engager Immuno-Oncology Platform at the 2025 SITC Annual Meeting
Biomunex to Present Breakthrough Preclinical Data on Its MAIT Engager Immuno-Oncology Platform at the 2025 SITC Annual Meeting Biomunex Pharmaceuticals, a French biopharmaceutical company advancing the frontiers of cancer immunotherapy through its pioneering bispecific and multispecific antibody technologies, has announced…












